These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39097324)

  • 1. Psoriasis and psoriatic arthritis following use of dostarlimab for endometrial cancer.
    Goel AR; Sylvester C; Avidan OR; Gilvaz VJ
    BMJ Case Rep; 2024 Aug; 17(8):. PubMed ID: 39097324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.
    Popa LG; Giurcaneanu C; Portelli MG; Mihai MM; Beiu C; Orzan OA; Ion A; Anghel TH
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541099
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series.
    Li YJ; Msaouel P; Campbell M; Hwu P; Diab A; Kim ST
    RMD Open; 2024 Aug; 10(3):. PubMed ID: 39214611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
    Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
    Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
    Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
    Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF
    JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis.
    Zheng J; Gao Y; Ding Y
    Dermatol Ther; 2019 Nov; 32(6):e13132. PubMed ID: 31631466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors of immune-related adverse events induced by immune checkpoint inhibitors among older adults with non-small cell lung cancer.
    Rong Y; Bentley JP; Bhattacharya K; Yang Y; Chang Y; Earl S; Ramachandran S
    Cancer Med; 2024 Jan; 13(1):e6879. PubMed ID: 38164655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
    Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
    Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma.
    Seervai RNH; Heberton M; Cho WC; Gill P; Murphy MB; Aung PP; Nagarajan P; Torres-Cabala CA; Patel AB; Ruiz-Bañobre J; Om A; Yamamoto T; Nikolaou V; Curry JL
    J Cutan Pathol; 2022 May; 49(5):472-481. PubMed ID: 34888886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy.
    Ma VT; Lao CD; Fecher LA; Schiopu E
    Immunotherapy; 2022 Jun; 14(8):593-598. PubMed ID: 35416067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
    Puig L; Morales-Múnera CE; López-Ferrer A; Geli C
    Dermatology; 2012; 225(1):14-7. PubMed ID: 22890275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid-dependent polyarthritis induced by immune checkpoint inhibitor therapy successfully treated with bimekizumab.
    Springer R; Lange K; Homey B; Meller S; Lindhof HH
    Immunotherapy; 2024 Mar; 16(5):287-293. PubMed ID: 38264842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
    Nikolaou V; Sibaud V; Fattore D; Sollena P; Ortiz-Brugués A; Giacchero D; Romano MC; Riganti J; Lallas K; Peris K; Voudouri D; Lallas A; Fabbrocini G; Lazaridou E; Carrera C; Annunziata MC; Rossi E; Patri A; Rigopoulos D; Stratigos AJ; Apalla Z
    J Am Acad Dermatol; 2021 May; 84(5):1310-1320. PubMed ID: 33279646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management.
    Williams SG; Mollaeian A; Katz JD; Gupta S
    Expert Rev Clin Immunol; 2020 Aug; 16(8):771-785. PubMed ID: 32772596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.